← Health care and life sciences companies

    Abivax: company profile, size and contacts

    abivax.comActiveFor profit

    Abivax develops medicines that alter the body's natural immune system mechanisms.

    Employees
    101-250
    Founded
    2013
    Total raised
    $376.2M
    Monthly visits
    615

    Company facts

    Website
    abivax.com
    Location
    European Union (EU), Europe, Middle East, and Africa (EMEA)
    Employees
    101-250
    Founded
    2013 (13 years ago)
    Categories
    Biotechnology, Health Care, Therapeutics
    Company type
    For profit
    Listing
    Public (NASDAQ:ABVX)
    Industry code (NAICS)
    6211 Offices of physicians; 3254 Pharmaceutical and medicine manufacturing
    Industry code (SIC)
    8000 Health services; 2834 Pharmaceutical preparations

    Founder

    • Philippe PoulettyFounder · Abivax

    Abivax was founded in 2013 by Philippe Pouletty.

    Funding

    Total raised
    $376.2M
    Funding rounds
    6
    Latest round
    Post ipo debt, 2023-08
    Investors
    14
    Lead investors
    5

    Web and app presence

    Monthly website visits
    615
    Global traffic rank
    #8,187,021

    How Abivax compares

    • Size: Abivax has more employees than 69% of the 1251 health care and life sciences companies in our directory that report it.
    • Age: Abivax is older than 26% of the 1166 health care and life sciences companies in our directory that report it.
    • Web traffic: Abivax gets more monthly website visits than 23% of the 1233 health care and life sciences companies in our directory that report it.

    1282 health care and life sciences companies are in the directory, 165 of them in the same 101-250 employee range and 184 based in European Union (EU).

    Growth outlook

    • Trend: Growing

    Abivax may be growing as it is listed among key companies in the Inflammatory Bowel Disease market, which is projected to exhibit significant growth by 2032. This inclusion suggests that Abivax is actively involved in a market with a positive growth trajectory. Furthermore, the company's association with the development of therapies in a growing market indicates ongoing research and development efforts. The market's expected growth could potentially lead to increased demand for Abivax's therapeutic solutions, contributing to the company's financial growth and expansion.

    What Abivax says about itself

    “Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA.” abivax.com

    Abivax in short

    Abivax has a 101-250 person team and operates in biotechnology, listed under European Union (EU), and has been around since 2013. Its website drew about 615 visits in the latest month measured and its founder is Philippe Pouletty.

    Frequently asked questions

    What does Abivax do?
    Abivax develops medicines that alter the body's natural immune system mechanisms.
    When was Abivax founded?
    Abivax was founded in 2013, so it is about 13 years old.
    How many employees does Abivax have?
    Crunchbase lists Abivax in the 101-250 employee range.
    Where is Abivax based?
    Abivax is listed under European Union (EU), Europe, Middle East, and Africa (EMEA).
    Has Abivax raised funding?
    Crunchbase records $376.2M raised across 6 funding rounds, most recently post ipo debt in 2023-08.
    How do I find email addresses at Abivax?
    Search the domain abivax.com with the Inbound Labs Domain Search or Email Finder to see verified contacts and departments. Individual addresses are shown after you sign up.

    Similar companies

    More in Health care and life sciences companies.

    Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.